GRI Bio, Inc.
Sean Edwards has an extensive work experience spanning several companies and roles. Currently, they serve as the Chief Executive Officer of Regencor Inc., a regenerative medicine company focusing on heart disease. Sean is responsible for driving the company's mission to reduce morbidity and mortality from myocardial infarction and prevent the progression to heart failure. Prior to this, Sean was a Board Member at Contract Pharmaceuticals Limited and served as the President of GRI Bio, Inc. Sean has also been a Member of YPO since 2011. Notably, Sean held the positions of Executive Chairman & Board Member and Interim Chief Executive Officer at NeuraLace Medical, Inc., a company working on non-invasive medical devices for chronic pain treatment. Sean has also served as the President of EvoMed (Holding) LLC and Cosmederm Bioscience, where they held the positions of President/CEO and VP of Business Development and General Counsel. Previously, Sean worked as the Director of Business Development at Innovaro.
Sean Edwards attended Princeton University from 1988 to 1992, where they obtained an A.B. degree in History with a concentration in American History. Sean then pursued further education at the University of San Diego School of Law from 1994 to 1996 and earned a Doctor of Law (JD) degree.
This person is not in the org chart
This person is not in any teams
GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.